Can Immunotherapy Be Combined With Chemotherapy?

Yes — for several major cancers, combining immune checkpoint inhibitors with chemotherapy is not experimental but standard, FDA-approved first-line treatment, backed by large randomized trials showing meaningful survival gains over chemotherapy alone. This article explains the biological rationale for pairing the two approaches, walks through the real trial data behind approved regimens like pembrolizumab-plus-chemotherapy for metastatic non-small cell lung cancer (NSCLC), lays out the genuine added toxicity that comes with combining modalities, and distinguishes what is established practice from what remains investigational.

Why Combine Two Different Kinds of Treatment?

Chemotherapy and immunotherapy attack cancer through different mechanisms, and there's a biological argument for why pairing them can do more than either alone. Certain chemotherapy drugs, at the right dose and schedule, don't just kill cancer cells outright — they can kill them in a way that alerts the immune system. This process, called immunogenic cell death, involves dying tumor cells releasing "danger signals" such as calreticulin exposed on the cell surface, ATP, and the protein HMGB1, along with tumor antigens. Together these signals can recruit dendritic cells and cytotoxic T cells into the tumor, converting an "immunologically cold" tumor into a "hot" one that immune checkpoint inhibitors like pembrolizumab or nivolumab are better positioned to act on. That rationale comes with real caveats. Not every chemotherapy drug induces immunogenic cell death equally well — the evidence for some commonly used agents remains genuinely debated among researchers. Dose and schedule appear to matter too, and the order in which the two treatments are given can change the outcome. In short, the biological logic for combining chemo and immunotherapy is real, but it does not mean any chemo drug paired with any checkpoint inhibitor will automatically work better together — the benefit has to be demonstrated regimen by regimen, cancer by cancer, in actual clinical trials.

The Established Standard: Pembrolizumab Plus Chemotherapy in Lung Cancer

The clearest, best-documented example of chemo-immunotherapy combination therapy is pembrolizumab (Keytruda) added to platinum-based chemotherapy for previously untreated metastatic non-squamous NSCLC, which the FDA approved on August 20, 2018 based on the KEYNOTE-189 trial. The results were striking enough to change first-line practice: adding pembrolizumab to pemetrexed-platinum chemotherapy cut the risk of death by 51% relative to chemotherapy alone (hazard ratio 0.49; p<0.00001), and cut the risk of progression by nearly half. At 12 months, 69.2% of patients on the combination were alive versus 49.4% on chemotherapy alone. Longer follow-up has held up: five-year outcomes reported at ASCO in 2022 showed 19.4% of patients on the combination were still alive at five years, compared with 11.3% on chemotherapy alone — median overall survival of 22.0 months versus 10.6 months. Response rates followed the same pattern, with tumors shrinking in 48% of patients on the combination versus 19% on chemotherapy alone. Lung cancer isn't the only place this pattern shows up. Atezolizumab plus bevacizumab and chemotherapy (the IMpower150 regimen) also improved overall survival over chemotherapy plus bevacizumab in first-line metastatic non-squamous NSCLC, and nivolumab plus ipilimumab combined with a short course of chemotherapy (CheckMate 9LA), approved by the FDA on May 26, 2020, improved median overall survival to 14.1 months versus 10.7 months with chemotherapy alone (hazard ratio 0.69). These are independent trials of different checkpoint inhibitors and different chemo backbones, all converging on the same conclusion for this cancer type: in appropriately selected NSCLC patients, adding immunotherapy to chemotherapy extends survival compared with chemotherapy alone.

The Real Cost: Added Toxicity

None of this comes without tradeoffs, and reputable sources are explicit about them. In KEYNOTE-189, grade 3–5 adverse events occurred in about 72% of patients on the pembrolizumab-chemotherapy combination versus roughly 67% on chemotherapy alone. More specific to the immunotherapy component, immune-mediated adverse events and infusion reactions of grade 3 or higher occurred in about 12.1% of patients on the combination versus 4.5% on chemotherapy alone. The NCI's own reporting on the trial flagged a notable safety signal: acute kidney injury occurred in 5.2% of patients on the pembrolizumab combination versus 0.5% on chemotherapy alone, prompting recommendations for closer kidney monitoring, particularly in patients with existing kidney disease risk. Immune-related adverse events are mechanistically different from classic chemotherapy side effects — instead of predictable myelosuppression or nausea, checkpoint inhibitors can cause the immune system to attack healthy tissue, producing thyroid dysfunction, pneumonitis, colitis, hepatitis, or other autoimmune-type complications that require different management, sometimes including corticosteroids or holding treatment altogether. The bottom line is that combining the two modalities is not toxicity-neutral — it adds a layer of immune-related risk on top of standard chemotherapy toxicity, even when the survival benefit is real.

Not Every Cancer, Not Every Regimen

It's also important not to over-generalize from lung cancer's success story. The strength of evidence for chemo-immunotherapy combinations varies considerably by cancer type, checkpoint inhibitor, and chemotherapy backbone — some combinations have clearly demonstrated survival benefit in phase 3 trials, while others have been tested and shown no meaningful advantage, or are still being studied. Patients should not assume that because one chemo-immunotherapy pairing works well in one cancer, a similar pairing will automatically work as well in a different disease setting.

What Patients Should Ask Their Oncologist

Because chemo-immunotherapy combinations are now standard-of-care for specific, FDA-approved indications rather than a single one-size-fits-all approach, the right question for a patient to bring to an oncology visit isn't "should I combine chemo and immunotherapy" in the abstract, but rather: "Is there an FDA-approved combination regimen with proven trial data for my specific cancer type and stage, and what does the evidence show about survival benefit versus added side-effect risk in my case?" It's also worth asking directly about biomarker testing (such as PD-L1 expression or EGFR/ALK mutation status), what immune-related side effects to watch for, and how they'll be monitored and managed if they occur.

Bottom Line

For specific, well-defined cancers — most prominently first-line metastatic NSCLC — combining immunotherapy with chemotherapy is FDA-approved, evidence-backed standard care that has been shown in large randomized trials to meaningfully extend survival compared with chemotherapy alone. That benefit is real and worth discussing seriously with an oncologist. But it comes bundled with a real increase in high-grade and immune-related toxicity, it is not established or automatically beneficial for every cancer type or drug pairing, and eligibility often depends on specific biomarkers and tumor genetics. Before starting any combination regimen, ask your oncologist what trial data exists for your specific diagnosis, what your personal risk of immune-related side effects looks like, and how those risks will be monitored throughout treatment.